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Abstract 30 
Tobacco exposure during pregnancy is associated with obstetric and fetal complications. 31 
We developed and validated an LC-MS/MS method to determine nicotine, cotinine and 32 
hydroxycotinine (OH-cotinine) in placenta (PL) and umbilical cord (UC). Specimens 33 
were homogenized in water, followed by solid phase extraction. Chromatographic 34 
separation was performed using an Atlantis® HILIC Silica column. Detection was 35 
accomplished in electrospray in positive mode. Method validation included: linearity (5 36 
to 1000 ng/g), accuracy (86.9 to 105.2% of target concentration in PL, and 89.1 to 37 
105.0% in UC), imprecision (6.8 to 11.8% in PL, and 7.6 to 12.2% in UC), limits of 38 
detection (2 ng/g for cotinine and OH-cotinine, and 5 ng/g for nicotine) and 39 
quantification (5 ng/g), selectivity (no endogenous or exogenous interferences), matrix 40 
effect (-34.1 to -84.5% in PL, %CV=9.1-24.0%; -18.9 to -84.7% in UC, %CV=10.2-41 
23.9%), extraction efficiency (60.7 to 131.5% in PL, and 64.1 to 134.2% in UC), and 42 
stability 72 h in the autosampler (<11.5% loss in PL, and <13% loss in UC). The 43 
method was applied to 14 PL and UC specimens from tobacco users during pregnancy. 44 
Cotinine (6.8-312.2 ng/g in PL; 6.7-342.3 ng/g in UC) was the predominant analyte, 45 
followed by OH-cotinine (<LOQ-80.2 ng/g in PL; <LOQ-80.5 ng/g in UC) and nicotine 46 
(5.7-63.7 ng/g in PL; 5.1-63.3 ng/g in UC). This method will be applied to more than 47 
150 specimens collected from a wide clinical study to evaluate the usefulness of 48 
maternal hair, meconium, placenta and umbilical cord compared to the maternal 49 
interview to detect in utero drug exposure.  50 







1. Introduction 58 
Active and passive tobacco exposure during pregnancy are associated with short and 59 
long term complications, including miscarriage, placental pathologies, decreased birth 60 
weight, fetal hypoxia, changes in the fetal heart rate, sudden infant death syndrome 61 
(SIDS), learning difficulties, respiratory diseases, increased risk of addictive behavior in 62 
adults and increased risk of cancer [1-5]. 63 
Surveys about tobacco use in the general population are abundant, and prevalences of 64 
tobacco consumption by women of childbearing age can be obtained from these data. 65 
The World Health Organization, in its Global Health Observatory (GHO) data, estimates 66 
that 19.3% of European women and 6.8% of women worldwide are smokers [6]. In 67 
Spain, tobacco is the psychoactive substance with the highest prevalence of daily 68 
consumption by females between 15 and 44 years (28.3% of daily consumption during 69 
the last month) [7]. However, information on tobacco use among pregnant women is 70 
scarce. Currently, the National Survey on Drug Use and Health survey in the USA 71 
collects data about prevalence of tobacco consumption by pregnant women. The last 72 
National Survey reported that 13.6% of pregnant women aged 15 to 44 in the US 73 
smoked tobacco during pregnancy [8]. 74 
A direct method to obtain information about drug use during pregnancy is through 75 
maternal interviews; nevertheless, this method has low reliability due to poor veracity of 76 
maternal answers associated with negative social connotations of drug use during 77 
pregnancy [9-12]. A more objective way to identify in-utero drug exposure is the 78 
determination of drug biomarkers in biological matrices from the mother, the newborn 79 
(blood, urine, meconium), or from the maternal-fetal dyad (placenta, umbilical cord) 80 
[13-16]. 81 
Meconium is the preferable matrix to detect in utero drug exposure, as it reflects direct 82 
fetal exposure during the third trimester of pregnancy [17, 18], providing a window of 83 
detection longer than classic matrices such as neonatal blood (hours) or urine (days). 84 
Nonetheless, meconium collection may prove challenging, as its expulsion can be 85 
delayed up to 5 days after delivery, or it can become unavailable in cases of fetal 86 
distress, as discharge may occur before delivery. Maternal hair analysis gives an indirect 87 
estimation of fetal drug exposure [17]; however, due to its long window of detection, 88 
this matrix could provide information about maternal drug use during the whole 89 
pregnancy, depending on hair’s length, thus complementing the information provided by 90 
meconium analysis [19]. 91 
Alternative matrices to those mentioned before are placenta and umbilical cord. These 92 
matrices have several advantages, as they are considered waste products, readily 93 
available at the time of birth in abundant amounts, and collection is easy and non-94 
invasive. Although studies conducted to date suggest that placenta and umbilical cord 95 
have a larger window of detection than blood or urine [20-25], more studies are needed 96 
to assess their usefulness.   97 
To our knowledge, this is the first study to measure nicotine, cotinine and 98 
hydroxycotinine (OH-cotinine) levels in both placenta and umbilical cord tissue. Three 99 
methods have been published for the determination of tobacco biomarkers in placenta 100 
[26-28], and two in umbilical cord [25, 29]. Although these methods have been applied 101 
for the analysis of authentic specimens, full method validation data were not reported 102 
[27, 28]. Moreover, the reported investigations either included the detection of only 103 
nicotine and cotinine [26, 27], or just cotinine [28, 29]; only one article included 104 
nicotine, cotinine and OH-cotinine, as well as nornicotine and anabasine [25]. 105 
The aim of this work was to develop and validate an LC-MS/MS method for the 106 
determination of nicotine, cotinine and OH-cotinine in placenta and umbilical cord. As a 107 
proof of concept, the method was applied to authentic placenta and umbilical cord 108 
samples from newborns exposed to tobacco during pregnancy. 109 
2. Materials and methods 110 
2.1. Chemicals 111 
Nicotine, cotinine and OH-cotinine standards at 1 mg/mL, and the deuterated internal 112 
standards (IStd) nicotine-d4, cotinine-d3 and OH-cotinine-d3 at 0.1 mg/mL in methanol 113 
were purchased from CerilliantTM (Round Rock, TX, USA). Water was purified with a 114 
Milli-Q water system (Milli-pore, Le-Mont-sur-Lausanne, Switzerland). Chromasolv® 115 
gradient grade methanol and reagent grade dichloromethane were from Sigma-Aldrich 116 
(Steinheim, Germany). Chromasolv® LC-MS grade 2-propanol was from Fluka (St. 117 
Louis, MO, USA). Reagent grade formic acid 98-100%, reagent grade hydrochloric acid 118 
37% and LC-MS grade ammonium formate were from Scharlau Chemie (Sentmenat, 119 
Spain). Ammonium hydroxide 32% and LC-MS grade acetonitrile were from Panreac 120 
(Castellar del Vallés, Spain). Solid phase extraction (SPE) Oasis MCX cartridges (3 cc, 121 
60 mg) were purchased from Waters Corp. (Milford, MA, USA). 122 
2.2. Placenta and umbilical cord samples  123 
Paired placenta, umbilical cord, meconium and maternal hair specimens from more than 124 
800 pregnancies were collected as part of a broad study to evaluate the prevalence of 125 
drug use during pregnancy, the usefulness of the different matrices to detect in utero 126 
drug exposure, and the possible correlation between drug use and neonatal outcomes.  127 
Specimens were collected from pregnant women who delivered at the University 128 
Clinical Hospital of Santiago de Compostela and the University Hospital Complex of 129 
Vigo, Spain, between 2012 and 2015, and the analyses were performed in our 130 
laboratory. The whole placenta and umbilical cord specimens were collected at delivery 131 
in polypropylene containers and stored at -20 °C until analysis. The participants were 132 
informed about the study both in writing and orally before delivery, and they gave 133 
written consent. The subjects were not paid for their participation. The study was 134 
approved by the Ethics Committee of the University of Santiago de Compostela, Spain. 135 
For the preparation of calibration curves and quality control samples (QCs), and for the 136 
evaluation of method selectivity, blank specimens are needed. Placenta and umbilical 137 
cord specimens whose paired maternal hair samples were negative for nicotine and 138 
cotinine were initially analyzed to confirm the absence of these analytes. 139 
2.3. Preparation of calibration and QC solutions 140 
For the preparation of the calibration curves, different working solutions in methanol 141 
containing all analytes (nicotine, cotinine and OH-cotinine) were generated at 10 142 
µg/mL, 1 and 0.1 µg/mL. Calibration curves were prepared with seven concentration 143 
levels (5, 10, 50, 100, 500 and 1000 ng/g) by addition of 50 or 100 µL of the 144 
corresponding working solution to placenta or umbilical cord blank samples.   145 
Working solutions at 0.5, 5 and 25 µg/mL in methanol were used for the preparation of 146 
low, medium and high concentration QC samples (15, 150 and 750 ng/g, respectively). 147 
Thirty µL of the appropriate working solution were added to the blank sample. 148 
Finally, a working solution containing the deuterated internal standards (IStd) (nicotine-149 
d4, cotinine-d3 and OH-cotinine-d3) at 1 µg/mL was prepared by dilution of the original 150 
individual ampoules in methanol. 151 
2.4. Sample homogenization 152 
Placenta or umbilical cord was cut into small pieces and 1.00 ± 0.02 g weighed into 153 
plastic tubes. Samples were subsequently homogenized in 5 mL purified Mili-Q water 154 
with an Ultra-Turrax® disperser at maximum speed until total tissue homogenization. 155 
The dispersed samples were transferred into Pyrex® glass tubes, and 50 µL of the IStd 156 
at 1 µg/mL and 50 µL of 10% formic acid in water were added. For the calibrators and 157 
the QC samples, the homogenized tissue was fortified with the appropriate working 158 
solution. The tubes were centrifuged for 15 minutes at 4000 rpm. All the supernatant 159 
was collected and subjected to SPE. 160 
2.5. Solid phase extraction procedure 161 
SPE was performed with Oasis MCX cartridges (3 cc, 60 mg). Cartridges were 162 
conditioned with 2 mL methanol and 2 mL water. The sample was loaded in two steps 163 
due to the 3 cc volume limitation of the cartridges. Cartridges were subsequently 164 
washed with 2 mL 0.1% formic acid in water (v:v). After drying the cartridges for 20 165 
min, analytes were eluted with 3 mL dichloromethane:2-propanol:ammonium hydroxide 166 
(23.75:71.25:5, v:v:v). Samples were then acidificated by addition of 100 µL 1% 167 
hydrochloric acid in methanol (v:v) to prevent evaporation of analytes. Eluates were 168 
evaporated using a TurboVap LV evaporator (Zymark, Hopkinton, MA, USA) and 169 
reconstituted in 200 µL acetonitrile with 0.1% formic acid:methanol (3:1, v:v). After 170 
centrifugation for 10 minutes at 14000 rpm, extracts were transferred into injection 171 
vials, and 20 µL were injected for LC-MS/MS analysis. 172 
2.6. LC-MS/MS 173 
An Alliance 2795 Separation Module with an Alliance series column heater/cooler 174 
(Waters Corp.) was employed for the chromatographic separation using an Atlantis® 175 
HILIC Silica (2.1 mm x 100 mm, 3 µm) column (Waters Corp.), maintained at 30 ºC. 176 
Formic acid (0.1%) and 2 mM ammonium formate in water (A) and 0.1% formic acid in 177 
acetonitrile (B) were used as mobile phase at a flow rate of 0.3 mL/min. The 178 
chromatographic gradient was programmed as follows: 5% A linearly increased to 60% 179 
until min 10; return to initial conditions at min 10.5, and equilibrate until min 15. The 180 
autosampler temperature was maintained at 6 ºC. 181 
The mass spectrometer employed was a Quattro Micro™ API ESCI triple quadrupole 182 
(Waters Corp.). The instrument was operated in electrospray in positive mode (ESI+) 183 
with the following optimized settings: capillary voltage 3.0 kV; source block and 184 
desolvation gas (nitrogen) temperature 130 ºC and 300 ºC, respectively; desolvation and 185 
cone gas (nitrogen) flow rate 500 L/h and 50 L/h, respectively. Data were recorded on 186 
multiple reaction monitoring (MRM) mode. A 10 µg/mL post-column infusion of each 187 
individual analyte at 100 µL/min connected with a “T” valve to the chromatographic 188 
effluent (0.1% formic acid in water:ACN, 50:50, v:v) was employed to select MRM 189 
transitions, cone voltages and collision energies for the analytes of interest and IStds. 190 
MassLynx 4.0 software was employed to control data acquisition and QuanLynx 4.1 for 191 
data processing (Waters Corp.). 192 
2.7. Method validation 193 
Method validation was performed according to the Scientific Working Group for 194 
Forensic Toxicology (SWGTOX) standard practices for method validation in forensic 195 
toxicology [30] and the European Medicines Agency (EMA) guideline on bioanalytical 196 
method validation [31]. The following paramenters were evaluated for method 197 
validation: linearity, accuracy, imprecision, limit of detection (LOD) and limit of 198 
quantification (LOQ), selectivity, matrix effect, extraction efficiency, process efficiency 199 
and stability in the autosampler for 72h. All parameters were studied in placenta and in 200 
umbilical cord.  201 
Linearity was assessed by the evaluation of calibration curves with 7 calibration levels 202 
analyzed on four different days. Concentration ranges were from 5 to 1000 ng/g for all 203 
analytes. The straight-line fit was performed by linear regression, applying a 1/x-204 
weighting factor. Linearity was acceptable if coefficient of determination (r2) was 205 
≥0.99, and calibrators’ residuals ±15%, except for the LOQ, for which residuals ±20% 206 
were accepted. 207 
Accuracy and imprecision were evaluated at low, medium and high QC concentrations 208 
(15, 150 and 750 ng/g, respectively). These parameters were assessed by the analysis of 209 
5 replicates for each QC analyzed on 4 different days (n=20). Accuracy was required to 210 
be within 85-115% of the nominal concentration (80-120% for the LOQ). Intra-assay, 211 
inter-assay and total imprecision were determined by calculating the coefficient of 212 
variation (%CV) following Krouwer and Rabinowitz’ recommendations [32], and using 213 
SPSS v. 20.0 statistical software. Requirement of %CV was to be less than 15% (20% 214 
for the LOQ). 215 
The limit of detection (LOD) was defined as the lowest concentration at which the two 216 
MRM transitions monitored for each analyte can be identified with a S/N (signal-to-217 
noise ratio) ≥3, an appropriate ion ratio, and within ±0.2 min of the mean calibrators 218 
retention time.  219 
The limit of quantification (LOQ) was defined as the lowest concentration that could be 220 
quantified with an imprecision (% CV) ≤20% and accuracy between 80 and 120% of the 221 
theoretical value. The LOQ was evaluated by the analysis of 5 replicates of blank 222 
placenta samples and 5 replicates of blank umbilical cord samples from different 223 
individuals fortified at the lowest concentration of the calibration curve. 224 
Selectivity of the method was evaluated for both exogenous and endogenous 225 
interferences. To evaluate the effect of endogenous interferences, blank placenta and 226 
umbilical cord samples from 10 different individuals were fortified with the IStds and 227 
analyzed. To evaluate the presence of exogenous interferences, blank placenta and 228 
umbilical cord samples were fortified with common drugs of abuse and medicines 229 
(morphine, codeine, 6-acetylmorphine, methadone, 2-ethylidene-1,5-dimethyl-3,3-230 
diphenylpyrrolidine, amphetamine, methamphetamine, 3,4-231 
methylendioxyamphetamine, 3,4-methylendioxymethamphetamine, 3,4-232 
methylendioxyethylamphetamine, cocaine, benzoylecgonine, ecgonine methylester, 233 
cocaethylene, lysergic acid diethylamide, ketamine, norketamine, 234 
gammahydroxybutyric acid, fentanyl, amitriptyline, paroxetine, zolpidem, zopiclone, 235 
ibuprofen, omeprazole, paracetamol, diclofenac, naproxen, alprazolam, temazepam, 236 
lormetazepam, lorazepam, clonazepam, diazepam, nordiazepam, flunitrazepam, 7-237 
aminoflunitrazepam, oxazepam, triazolam, nitrazepam, bromazepam) at 1000 ng/g. 238 
Matrix effect, extraction efficiency and process efficiency were evaluated in placenta 239 
and in umbilical cord at low and high QC concentrations (15 and 750 ng/g, 240 
respectively), following recommendations published by Matuszewski et al. [33]. 241 
Evaluation of matrix effect was performed by comparing average analyte peak area in 242 
blank samples from 10 different individuals fortified with the analytes after extraction, 243 
with average peak area of the analytes prepared at the same concentration in acetonitrile 244 
with 0.1% formic acid:methanol (3:1, v:v) (n=5). Extraction efficiency was evaluated by 245 
comparing average analyte peak area in blank samples fortified with the analytes before 246 
extraction (n=5) with average peak area obtained in blank samples fortified after 247 
extraction (n=10). Process efficiency was calculated by comparing average analyte peak 248 
area in blank samples fortified with the analytes before extraction (n=5) with average 249 
peak area of the analytes prepared at the same concentration in acetonitrile with 0.1% 250 
formic acid:methanol (3:1, v:v) (n=5). 251 
Autosampler stability of the compounds was evaluated at low, medium and high QC 252 
concentrations by comparing concentrations obtained after the injection of freshly 253 
prepared QC samples (n=5) and after reinjection 72 hours later. The stability was 254 
considered acceptable if the reinjected QCs were quantified within ±15% compared to 255 
freshly prepared QCs. 256 
2.8. Application to authentic samples 257 
To confirm method applicability, 14 authentic umbilical cord and placenta samples from 258 
pregnant tobacco users were analyzed. Tobacco use was confirmed by the analysis of 259 
the paired maternal hair specimen using a previously published method which was 260 
further expanded to include nicotine and cotinine determination [34]. Hair specimens 261 
were divided into 3 segments corresponding with the 3 trimesters of pregnancy. 262 
Segment 1, corresponding to the last trimester of pregnancy, was from 0 (root) to 2 cm; 263 
segment 2, corresponding to the 2nd trimester, from 3 to 6 cm; and segment 3, 264 
corresponding to the 1st trimester, was from 6 to 9 cm. However, if the amount of hair 265 
specimen was not enough for segmentation only one segment up to 8 cm long, 266 
corresponding to the whole pregnancy,  was analyzed. 267 
To ensure that the analysis of a single intermediate location would be accurately 268 
representative of placental and umbilical cord disposition, we initially assessed whether 269 
the analytes of interest were homogeneously distributed throughout the tissues. For this 270 
purpose, analytes concentrations in 9 placenta samples at 4 different locations (1, 4, 6, 271 
and 10 cm from the umbilical cord) and in the paired umbilical cord at two locations 272 
(start and end of the tissue) were evaluated.  273 
3. Results 274 
3.1. Method development 275 
The present analytical methods allowed the determination of nicotine, cotinine and OH-276 
cotinine in 1 g placenta or umbilical cord. Both methods employed the same analytical 277 
procedure, including chromatographic separation, and sample homogenization and 278 
extraction, and they were completely validated in each matrix. Chromatographic elution 279 
of all the analytes was achieved in 7.5 min, with a total chromatographic run time of 15 280 
min. 281 
The most abundant MRM transition was used for quantification. A second transition 282 
was monitored for qualitative purposes to fulfill the European Commission Decision 283 
2002/657/EC identification criteria using mass spectrometric techniques [35]. 284 
Table 1 shows quantification and qualification transitions, cone voltage, collision energy 285 
and retention time for each analyte. 286 
3.2. Method validation 287 
Selectivity of the method was verified as no quantifiable endogenous or exogenous 288 
interferences were detected at the specific retention time for each analyte in 10 different 289 
blank placenta and umbilical cord specimens (Figures 1a and 2a), or in the blank 290 
samples fortified with common drugs of abuse and medicines. 291 
LOD was 5 ng/g for nicotine, and 2 ng/g for the metabolites, and the LOQ was 5 ng/g 292 
for all the analytes in both matrices. Figures 1b and 2b correspond to blank placenta and 293 
umbilical cord samples fortified at the LOQ. 294 
Linearity of the compound-to-IStd ratio versus the theoretical concentration was 295 
verified through 4 calibration curves analyzed in 4 different days with 1/x weighting 296 
factor. For all the analytes the curves were fitted to a linear regression model over the 297 
concentration range of 5 to 1000 ng/g, obtaining a mean r2 ≥0.995 for all the analytes. 298 
Residuals were ±20 % at the LOQ and ±15 % for the rest of the calibrators. Table 2 299 
shows linearity range and calibration parameters results for nicotine, cotinine and OH-300 
cotinine in placenta and in umbilical cord.  301 
Results for accuracy and imprecision in placenta and umbilical cord are shown in Table 302 
3. Accuracy was satisfactory for all the analytes in both matrices (86.9-105.2% of the 303 
target concentration in placenta, and 89.1-105.0% in umbilical cord). Intra-assay, inter-304 
assay and total imprecision were <6.8%, <10.3% and <11.8%, respectively, in placenta, 305 
and <7.6%, <9.6% and <12.2% in umbilical cord. 306 
Matrix effect, extraction efficiency and process efficiency results are shown in Table 4. 307 
All analytes showed ion suppression at low and high QC concentrations in both 308 
matrices. Matrix effect ranged from -34.1 to -84.5% (%CV=9.1-24.0%) in placenta, and 309 
from -18.9 to -84.7% (%CV=10.2-23.9%) in umbilical cord. In all cases, behavior of the 310 
deuterated internal standards was similar to that observed for the non-labeled analyte, 311 
compensating matrix effect results. Extraction efficiency ranged from 60.7 to 99.5% in 312 
placenta, and from 64.1 to 103.9% in umbilical cord, except for nicotine-d4, for which 313 
values up to 131.5% and 134.2% were observed in placenta and in umbilical cord, 314 
respectively. These high extraction efficiency values were probably due to the higher 315 
variability observed in the different specimens used to evaluate this parameter compared 316 
to those employed to calculate the matrix effect for nicotine-d4. %CV for the 5 317 
replicates ranged from 12.7 to 29.9% in placenta, and 10.5 to 25.3% in umbilical cord. 318 
Overall process efficiency ranged from 13.2 to 59.6% and from 14.7 to 57.0% in 319 
placenta and umbilical cord, respectively. 320 
Results from the stability study in the autosampler showed that all the analytes were 321 
stable in these conditions for 72 h, with <13% loss when compared to fresh QC samples 322 
in all cases. 323 
3.3. Application to authentic samples 324 
Table 5 shows results observed in the experiment to evaluate whether the analytes were 325 
homogeneously distributed in 9 pairs of placenta and umbilical cord specimens 326 
(samples A to I). %CV for nicotine, cotinine and OH-cotinine concentrations observed 327 
at the 4 different placenta locations was <15%, except for OH-cotinine in placenta E 328 
(%CV= 22.3%), and nicotine in placenta F (%CV=20.9%) . In umbilical cord, %CV 329 
was <15% in all cases, except for nicotine in umbilical cord D (%CV= 28.0%).  330 
Due to the homogeneous distributions, a single intermediate location was analyzed for 331 
all the other placenta and umbilical cord specimens. Eight out of 14 placenta and 332 
umbilical cord specimens were positive for the 3 analytes (Table 5). Similar 333 
concentrations were observed in placenta and in umbilical cord. Nicotine, cotinine and 334 
OH-cotinine concentrations in placenta ranged from 5.7 to 63.7 ng/g, 6.8 to 312.2 ng/g 335 
and <LOQ to 80.2 ng/g, respectively; and concentrations in umbilical cord ranged from 336 
5.1 to 63.3 ng/g, 6.7 to 342.3 ng/g and <LOQ to 80.5 ng/g, respectively. Hair 337 
concentrations were decreasing throughout the pregnancy for participants for whom a 338 
segmental analysis could be performed, with the lowest concentrations observed in the 339 
third trimester, except for participant I (data not shown). For participants B, L, M and N 340 
only one segment of 8 cm length could be analyzed. Eight out of 14 hair specimens 341 
were positive for both nicotine and cotinine; however, as opposed to placenta and 342 
umbilical cord, the parent drug was the predominant analyte in hair, except for 343 
participant A. Hair concentrations were much higher than those found in placenta and in 344 
umbilical cord, ranging from 265.9 to 15428.3 ng/g for nicotine, and from 72.7 to 668.5 345 
ng/g for cotinine; however, hair concentrations were not correlated to those observed in 346 
placenta and in umbilical cord (Table 5). Figure 3 shows the chromatogram of the 2 347 
MRM transitions identified for each analyte after the analysis of the placenta and the 348 
umbilical cord of the real case L.  349 
4. Discussion 350 
The present analytical method allows for the simultaneous quantification of nicotine and 351 
its main metabolites cotinine and OH-cotinine in placenta and umbilical cord using LC-352 
MS/MS. For this purpose, samples were homogenized with water and extracted with 353 
solid phase extraction columns based on mixed mode reversed-phase and cation 354 
exchange mechanisms. Chromatographic separation was performed in 7.5 min using a 355 
HILIC column, and a LOQ of 5 ng/g was achieved with these conditions. Although a 356 
concentration of 2 ng/g in placenta or umbilical cord fulfilled the criteria for the LOD 357 
for the 3 analytes, we increased this value to 5 ng/g for nicotine as a minimal non-358 
quantifiable contamination for this compound was observed in the blank samples.  359 
For placenta and umbilical cord homogenization we tested several solutions, including 360 
water, 10% formic acid and methanol. Best results were obtained with water, as samples 361 
homogenized with formic acid prompted cartridge clogging, and those mixed with 362 
methanol were more difficult to blend. Samples were subsequently extracted by SPE. 363 
Different cartridges were evaluated for sample extraction, including OASIS MCX 3 cc 364 
60 mg, OASIS HLB 3 cc 60 mg (Waters Corp., Mildford, MA, USA) and Strata-X-C 3 365 
cc 60 mg (Phenomenex, Torrance, CA, USA), with the best results in terms of 366 
sensitivity observed for mixed mode reversed phase-cation exchange cartridges. OASIS 367 
MCX were finally selected, as cartridge clogging was usually observed when placenta 368 
or umbilical cord samples were extracted with Strata-X-C. To optimize analytes elution 369 
we assessed several combinations of NH4OH and methanol, and dichloromethane, 2-370 
propanol and NH4OH. Best results were obtained with dichloromethane:2-371 
propanol:NH4OH (23.75:71.25:5, v:v:v). 372 
For chromatographic separation, best results were observed using a HILIC analytical 373 
column. We also assayed several reversed-phase analytical columns; however, due to 374 
the polarity of the analytes, retention was very poor. 375 
Some analytical methods have been reported for the determination of nicotine and/or its 376 
metabolites in placenta and/or umbilical cord by GC or LC-MS [25-28]. Marin et al. 377 
[25] developed a method for the determination of nicotine and several metabolites 378 
including cotinine, OH-cotinine, nornicotine and anabasine in meconium and umbilical 379 
cord by LC-MS/MS. The samples (0.25 g of meconium or 1.5-2 g of umbilical cord) 380 
were homogenized with methanol, and afterwards extracted with mixed mode reversed-381 
phase cation exchange columns, although they employed Trace B instead OASIS MCX 382 
columns. Chromatographic separation was performed using a HILIC analytical column. 383 
Limits of quantification in umbilical cord were lower than those described in the present 384 
manuscript (0.5 ng/g for nicotine and OH-cotinine, and 0.25 ng/g for cotinine, 385 
nornicotine and anabasine). Concentrations found in 14 umbilical cord specimens from 386 
mothers who admitted smoking during the last trimester were higher than our LOQ for 387 
cotinine and OH-cotinine (>5 and >17 ng/g, respectively); however, nicotine 388 
concentrations in these cases were between 0.9 and 11.7 ng/g. Unfortunately, method 389 
validation was not described and, therefore, selectivity, and precision and accuracy of 390 
the quantitative results could not be assessed. Joya et al. [26] published a method for the 391 
determination of drugs of abuse including amphetamine and derivatives, opioids, 392 
cocaine and cannabis, nicotine and cotinine in placenta from women that voluntarily 393 
interrupted their pregnancy during the first trimester. Samples were homogenized with 394 
HClO4 0.1%, and subsequently extracted with Strata-X-C cation exchange cartridges. 395 
The authors used the same amount of placenta reported in the present study (1 g), and 396 
achieved similar limits of quantification (13.9 ng/g for nicotine and 2.1 ng/g for 397 
cotinine) and limits of detection (4.6 ng/g for nicotine and 0.7 ng/g for cotinine). The 398 
authors describe the results of some validation parameters (linearity, analytical recovery, 399 
LOQ, LOD, precision and accuracy, and stability). Recently, Mohammadi et al. [27] 400 
published a method for the determination of nicotine and cotinine, and several 401 
polycyclic aromatic hydrocarbons (PAHs) and tobacco-specific nitrosamines in placenta 402 
by UPLC-QTOF-MS. After placenta (5 g) protein precipitation with trichloroacetic acid, 403 
samples were blended and also extracted with cation exchange cartridges. A reversed-404 
phase analytical column (ACQUITY UPLC BEH C18) was employed for the 405 
chromatographic separation. High LOQs were obtained, with values of 88 and 26 ng/g 406 
for nicotine and cotinine, respectively. LODs were also high (27 ng/g for nicotine and 8 407 
ng/g for cotinine). Unfortunately, method validation included only extraction recovery 408 
and matrix effect. Finally, Mamsen et al. [28] reported an LC-MS/MS method for the 409 
determination of cotinine and perfluorinated compounds (PFASs) in placenta, fetal 410 
tissues and maternal plasma, as maternal cigarette smoking may affect PFASs 411 
concentrations. However, calibration curves in plasma were used for the quantification 412 
of the analytes found in all type of samples, and no method validation was reported in 413 
any of the matrices. 414 
The present method was completely validated in placenta and in umbilical cord. Our 415 
method fulfilled the acceptance values for all the studied validation parameters, 416 
including selectivity, linearity, precision, accuracy, extraction efficiency, matrix effect 417 
and autosampler stability. In addition, real placenta and umbilical cord specimens were 418 
analyzed to prove the method applicability. The homogeneous distribution in placenta 419 
and in umbilical cord have been previously described for several drugs, including 420 
cocaine, opiates and methadone and metabolites [36, 37]. Concheiro et al. found a 421 
homogeneous distribution in these tissues for buprenorphine (BUP) metabolites BUP 422 
glucuronide, norBUP and norBUP glucuronide in placenta [38] and in umbilical cord 423 
[39]. However, BUP was not detected in some locations in 2 out of 5 placenta 424 
specimens; this was probably due to the low concentrations of BUP in the specimens (1-425 
2.4 ng/mL) that were close to the method LOQ (1 ng/mL). BUP was never detected in 426 
umbilical cord. In the present manuscript, we confirmed that nicotine and metabolites 427 
concentrations in different tissue locations are homogeneous and, therefore, one single 428 
intermediate location of the real specimens was analyzed. LOD and LOQ for the three 429 
analytes in placenta and umbilical cord were sufficient for identification of in utero fetal 430 
exposure, as at least 2 nicotine biomarkers were detected in the 14 authentic cases 431 
collected at delivery from tobacco user mothers. Similar concentrations were found in 432 
placenta and umbilical cord. Cotinine (6.8-312.2 ng/g in placenta; 6.7-342.3 ng/g in 433 
umbilical cord) was the predominant analyte, followed by OH-cotinine (<LOQ-80.2 434 
ng/g in placenta; <LOQ-80.5 ng/g in umbilical cord) and nicotine (5.7-63.7 ng/g in 435 
placenta; 5.1-63.3 ng/g in umbilical cord). Concentrations found in paired hair 436 
specimens were much higher than those observed in placenta and in umbilical cord; 437 
moreover, as expected, the parent drug was usually the predominant analyte in hair. For 438 
4 participants only one segment of 8 cm long corresponding to drug intake for the whole 439 
pregnancy could be analyzed. Therefore, hair concentrations corresponding to the third 440 
trimester of pregnancy were only available for 10 participants. In these cases, nicotine 441 
and cotinine concentrations in hair were not associated to those found in placenta and 442 
umbilical cord, as the highest concentrations in hair were observed for participant I 443 
followed by participants K>F>J>C>G>E>D>A>H, while the highest concentrations in 444 
placenta and in umbilical cord were found for participant C followed by participants 445 
F>D>G>A>K>E>J>I>H. 446 
Joya et al. [26] detected 21 positive placenta specimens (32.8% of the analyzed 447 
specimens) by the identification of cotinine (24.7-189.6 ng/g, median= 80.4 ng/g), and 448 
nicotine in some cases (32.5-119.5 ng/g, median=61.2 ng/g). The reason for the higher 449 
nicotine concentrations compared to those found in our specimens could be the origin of 450 
the samples, which were donated by women that voluntarily interrupted their pregnancy 451 
during the first trimester of pregnancy, and as previous studies showed, this is 452 
associated with higher rates of maternal smoking [8, 40, 41]. Marin et al. [25] compared 453 
nicotine and metabolite profile in 14 paired meconium and umbilical cord specimens 454 
from women that admitted tobacco consumption during their pregnancies. Cotinine 455 
(14.2-157.7 ng/g) and OH-cotinine (26.6-195.2 ng/g) were also the predominant 456 
analytes in umbilical cord, although nicotine and norcotinine were also detected in 12 457 
cases (0.9-11.7 ng/g and 0.3-1.3 ng/g, respectively). The same analytes were detected in 458 
meconium, although at higher concentrations and with a different metabolite profile, as 459 
in this matrix the predominant analytes were usually nicotine (20.8-590.1 ng/g) and 460 
OH-cotinine (34.9-354.2 ng/g). Mohammadi et al. [27] found cotinine (17.2-61.8 ng/g) 461 
and nicotine (27-88 ng/g) in 8 umbilical cord specimens from smoking mothers; and, as 462 
expected, none of the analytes were identified in the 18 specimens from mothers that 463 
did not smoke during the pregnancy. Finally, Mansem et al. [28] reported cotinine 464 
concentrations of 4-375 ng/g in 14 placenta specimens from smoking mothers. 465 
The present LC-MS/MS method was developed for the identification of newborns 466 
exposed to tobacco during the pregnancy by the analysis of placenta and umbilical cord. 467 
Its main limitation is that the sensitivity for nicotine could compromise its detection in 468 
some cases; however, in these cases, identification of in utero exposure would be 469 
guaranteed by the detection of its metabolites cotinine and/or OH-cotinine. The method 470 
will be applied to more than 150 placenta and umbilical cord specimens collected at 471 
delivery from mothers whose hair tested positive for nicotine and/or cotinine. This will 472 
increase our knowledge on nicotine and metabolites disposition in placenta and 473 
umbilical cord, and the usefulness of these alternative matrices for identification of in 474 
utero tobacco exposure. 475 
5. Conclusion 476 
To our knowledge, this is the first analytical method for the simultaneous determination 477 
of nicotine, cotinine and OH-cotinine in both placenta and umbilical cord. The methods 478 
were successfully validated, achieving satisfactory results for all the studied parameters. 479 
Analysis of authentic placenta and umbilical cord specimens from pregnant women 480 
whose hair tested positive to tobacco confirmed the applicability of these analytical 481 
methods, showing cotinine as the predominant analyte, with similar concentrations 482 
observed in both matrices. The present methods will be applied to more than 150 paired 483 
placenta and umbilical cord specimens to evaluate the usefulness of these alternative 484 
matrices to detect of in utero drug exposure, and to assess a possible correlation 485 
between detected concentrations and neonatal outcomes. 486 
Aknowledgement 487 
This project was funded by the Plan Nacional Sobre Drogas, Ministerio de Sanidad, 488 
Gobierno de España, grant 2016I005. E. Lendoiro would like to thank the Consellería 489 
de Cultura, Educación e Ordenación Universitaria, Xunta de Galicia, for her 490 



















[1] Sastry BVR, Janson VE. Smoking, Placental Function, and Fetal Growth. In: Sastry 510 
BVR, ed. Placental Toxicology. Boca Raton, Florida, USA: CRC Press; 1995:46-71.  511 
[2] Pérez López JA. Tabaco, alcohol y embarazo en Atención Primaria. Med Integr 512 
2000;36(9):343-354.  513 
[3] Reeves S, Bernstein I. Effects of maternal tobacco-smoke exposure on fetal growth 514 
and neonatal size. Expert Rev Obstet Gynecol 2008;3(6):719-730. 515 
doi:10.1586/17474108.3.6.719. 516 
[4] Narkowicz S, Plotka J, Polkowska Z, Biziuk M, Namiesnik J. Prenatal exposure to 517 
substance of abuse: A worldwide problem. Environ Int 2013;54:141-163. 518 
doi:10.1016/j.envint.2013.01.011. 519 
[5] WHO (World Health Organization). Media centre. Fact sheet: Tobacco, June 2016.  520 
http://www.who.int/mediacentre/factsheets/fs339/en/. Accessed April 28, 2017.  521 
[6] WHO (World Health Organization). Global Health Observatory (GHO) data. World 522 
Health Statistics 2016 data visualizations dashboard. Tobacco control. 523 
http://apps.who.int/gho/data/node.sdg.3-a-data?lang=en. Accessed August 8, 2017. 524 
[7] Observatorio Español de la Droga y las Toxicomanías (OEDT). Plan Nacional Sobre 525 
Drogas (PNSD). Alcohol, tabaco y drogas ilegales en España. Estadísticas 2015. 526 
www.pnsd.msssi.gob.es/profesionales/sistemasInformacion/informesEstadisticas/pdf/E527 
STADISTICAS_2015.pdf. Accessed April 26, 2017. 528 
[8] Center for Behavioral Health Statistics and Quality, Rockville, MD. 2015 National 529 
Survey on Drug Use and Health: Detailed Tables. Table 6.75B: Cigarette Use in Past 530 
Month among Females Aged 15 to 44. 531 
https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2015/NSDUH-532 
DetTabs-2015/NSDUH-DetTabs-2015.pdf. Accessed April 26, 2017. 533 
[9] Cruz A, Bouzas C, Concheiro M, et al. Adicc 2006;18(1):245-261.  534 
[10] Pichini S, Basagaña X, Pacifici R, et al. Cord Serum Cotinine as a Biomarker of 535 
Fetal Exposure to Cigarette Smoke at the End of Pregnancy. Environ Health Perspect 536 
2000;108:1079–1083. 537 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1240166/pdf/ehp0108-001079.pdf. 538 
Accessed April 28, 2017. 539 
[11] Manich A, Velasco M, Joya X, et al. Validez del cuestionario de consumo materno 540 
de alcohol para detectar la exposición prenatal. An Pediatr 2012;76(6):324-328. 541 
doi:10.1016/j.anpedi.2011.09.016. 542 
[12] Concheiro M, González-Colmenero E, Lendoiro E, et al. Alternative Matrices for 543 
Cocaine, Heroin, and Methadone In Utero Drug Exposure Detection. Ther Drug Monit 544 
2013;35:502-509. doi:10.1097/FTD.0b013e31828a6148. 545 
[13] Lendoiro E, González-Colmenero E, Concheiro-Guisán A, et al. Maternal Hair 546 
Analysis for the Detection of Illicit Drugs, Medicines, and Alcohol Exposure During 547 
Pregnancy. Ther Drug Monit 2013;35:296-304. doi:10.1097/FTD.0b013e318288453f. 548 
[14] Falcon M, Valero F, Pellegrini M, et al. Exposure to psychoactive substances in 549 
woman who request voluntary termination of pregnancy assessed by serum and hair 550 
testing. Forensic Sci Int 2010;196:22-6. doi:10.1016/j.forsciint.2009.12.042. 551 
[15] García-Algar O, Vall Combelles O, Puig Sola C, Mur Sierra A, Scaravelli G et al. 552 
Prenatal exposure to drugs of abuse using meconium analysis in a low socioeconomic 553 
population in Barcelona. Ann Pediatr 2009;70:145-152. 554 
doi:10.1016/j.anpedi.2008.08.008. 555 
[16] Lozano J, García-Algar O, Marchei E, et al. Prevalence of gestational exposure to 556 
cannabis in a Mediterranean city by meconium analysis. Acta Paediatr 2007;96:1734-557 
1737. doi:10.1111/j.1651-2227.2007.00535.x. 558 
[17] Lozano J, García-Algar O, Vall O, de la Torre R, Scaravelli G, Pichini S. 559 
Biological matrices for the evaluation of in utero exposure to drugs of abuse. Ther Drug 560 
Monit 2007;29:711-34. doi:10.1097/FTD.0b013e31815c14ce. 561 
[18] Bessa MA, Mitsuhiro SS, Chalem E, Barros MM, Guinsburg R, Laranjeira R. 562 
Underreporting of use of cocaine and marijuana during the third trimester of gestation 563 
among pregnant adolescents. Addict Behav 2010; 35:266–269. 564 
[19] Huestis MA, Choo RE. Drug abuse’s smallest victims: in utero drug exposure. 565 
Forensic Sci Int 2002;128:20–30. doi: 10.1016/S0379-0738(02)00160-3. 566 
[20] Jones J, Rios R, Jones M, Lewis D, Plate C. Determination of amphetamine and 567 
methamphetamine in umbilical cord using liquid chromatography-tandem mass 568 
spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:3701–3706. 569 
doi: 10.1016/j.jchromb.2009.09.021. 570 
[21] Concheiro M, Jones HE, Johnson RE, Choo R, Shakleya DM, Huestis MA.  571 
Maternal buprenorphine dose, placenta buprenorphine, and metabolite concentrations 572 
and neonatal outcomes. Ther Drug Monit 2010, 32(2):206-15. 573 
doi:10.1097/FTD.0b013e3181d0bd68. 574 
[22] Concheiro M, Jones HE, Johnson RE, Choo R, Shakleya DM, Huestis MA. 575 
Umbilical cord monitoring of in utero drug exposure to buprenorphine and correlation 576 
with maternal dose and neonatal outcomes. J Anal Toxicol 2010;34(8):498-505. doi: 577 
10.1093/jat/34.8.498. 578 
[23] de Castro A, Jones HE, Johnson RE, Gray TR, Shakleya DM, Huestis MA. 579 
Methadone, cocaine, opiates, and metabolite disposition in umbilical cord and 580 
correlations to maternal methadone dose and neonatal outcomes. Ther Drug Monit 581 
2011;33:443–452. doi:10.1097/FTD.0b013e31822724f0. 582 
[24] de Castro A, Concheiro M, Shakleya DM, Huestis MA. Development and 583 
validation of a liquid chromatography mass spectrometry assay for the simultaneous 584 
quantification of methadone, cocaine, opiates and metabolites in human umbilical cord. 585 
J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:3065–3071. 586 
doi:10.1016/j.jchromb.2009.07.028.25 587 
[25] Marin SJ, Christensen RD, Baer VL, Clark CJ, McMillin GA. Nicotine and 588 
Metabolites in Paired Umbilical Cord Tissue and Meconium Specimens. Ther Drug 589 
Monit 2011;33:80-85. doi:10.1097/FTD.0b013e3182055f14. 590 
[26] Joya X, Pujadas M, Falcón M, et al. Gas chromatography-mass spectrometry assay 591 
for the simultaneous quantification of drugs of abuse in human placenta at 12th week of 592 
gestation. Forensic Sci Int 2010;196:38-42. doi:10.1016/j.forsciint.2009.12.044. 593 
[27] Mohammadi S, Domeno C, Nerin I, et al. Toxic compounds from tobacco in 594 
placenta samples analyzed by UPLC-QTOF-MS. J Pharm Biomed Anal 2017;145:331-595 
338. doi:10.1016/j.jpba.2017.06.028. 596 
[28] Mamsen L, Jönsson B, Lindh C, et al. Concentration of perfluorinated compounds 597 
and cotinine in human foetal organs, placenta, and maternal plasma. Sci Total Environ 598 
2017;596-597:97-105. doi:10.1016/j.scitotenv.2017.04.058. 599 
[29] Wright TE, Milam KA, Rougee L, Tanaka MD, Collier AC. Agreement of 600 
umbilical cord drug and cotinine levels with maternal self-report of drug use and 601 
smoking during pregnancy. J Perinatol 2011;31(5):324-9. doi:10.1038/jp.2010.132. 602 
[30] Scientific Working Group for Forensic Toxicology (SWGTOX) standard practices 603 
for method validation in forensic toxicology. J Anal Toxicol 2013;37(7):452-74. doi: 604 
10.1093/jat/bkt054. 605 
[31] European Medicines Agency. Guideline on bioanalytical method validation, 2011. 606 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/607 
WC500109686.pdf (accesed on 14th December 2017). 608 
 [32] Krouwer JS, Rabinowitz R. How to improve estimates of imprecision. Clin Chem 609 
1984;30(2):290-292. 610 
[33] Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment 611 
of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal 612 
Chem 2003;75(13):3019–3030. doi:10.1021/ac020361s. 613 
[34] Lendoiro E, Quintela O, de Castro A, López-Rivadulla M, Concheiro M. Target 614 
screening and confirmation of 35 licit and illicit drugs and metabolites in hair by LC-615 
MS/MS. Forensic Sci Int 2012;217(1-3):207-15. doi: 10.1016/j.forsciint.2011.11.006. 616 
[35] European Union Decision 2002/657/EC (17/8/2002). Commision decision of 12 617 
August 2002 implementing Council Directive 96/23/EC concerning the performance of 618 
analytical methods and the interpretation of results. Off J Eur Commun 2002;221:8-36. 619 
[36] de Castro A, Jones HE, Johnson RE, Gray TR, Shakleya DM, Huestis M. Maternal 620 
methadone dose, placental methadone concentrations, and neonatal outcome. Clin Chem 621 
2011;57(3):449-58. doi: 10.1373/clinchem.2010.154864. 622 
[37] de Castro A, Jones HE, Johnson RE, Gray TR, Shakleya DM, Huestis M. 623 
Methadone, cocaine, opiates, and metabolite disposition in umbilical cord and 624 
correlations to maternal methadone dose and neonatal outcomes. Ther Drug Monit, 625 
2011;33(4):443-52. doi: 10.1097/FTD.0b013e31822724f0. 626 
[38] Concheiro M, Jones HE, Choo R, Shakleya DM, Huestis MA. Maternal 627 
buprenorphine dose, placenta buprenorphine, and metabolite concentrations and 628 
neonatal outcomes. Ther Drug Monit, 2010;32(2):206-15. doi: 629 
10.1097/FTD.0b013e3181d0bd68. 630 
[39] Concheiro M, Jones HE, Johnson RE, Choo R, Shakleya DM, Huestis MA. 631 
Umbilical cord monitoring of in utero exposure to buprenorphine and correlation with 632 
maternal dose and neonatal outcomes. J Anal Toxicol, 2010;34(8):498-505. 633 
[40] Tong VT, Dietz PM, Farr SL, D’Angelo DV, England LJ. Estimates of smoking 634 
before and during pregnancy, and smoking cessation during pregnancy: comparing two 635 
population-based data sources. Public Health Rep 2013;128(3):179-188. 636 
doi:10.1177/003335491312800308. 637 
[41] Curtin SC, Matthews TJ. Smoking prevalence and cessation before and during 638 
pregnancy: data from the Birth Certificate, 2014. Natl Vital Stat Rep 2016;65(1):1-14.  639 
Table 1. MRM transitions, cone voltage (CV), collision energy (CE), retention time (Rt) 640 
for each analyte. 641 





Nicotine 163.1 > 132.2 163.1 > 116.7 30 
18 
26 7.2 
Nicotine-d4 167.2 > 120.7 30 28 7.3 
Cotinine 177.1 > 79.5 177.1 > 97.6 35 
22 
20 2.8 
Cotinine-d3 180.2 > 79.5 35 24 2.9 
OH-Cotinine 193.2 > 133.8 193.2 > 79.5 30 
18 
24 2.6 
OH-Cotinine-d3 196.1 > 79.5 35 24 2.7 
Underlined transitions were used for quantification. OH-Cotinine: hydroxycotinine 
 642 
 643 
Table 2. Linearity range and calibration parameters for nicotine, cotinine and 644 
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Table 3. Results for imprecision and accuracy in placenta and umbilical cord at low (15 656 





















(n =20; %CV) 
Inter-assay 
imprecision 
(n =20; %CV) 
Total imprecision 
(n = 20; %CV) 
Accuracy 



























PL 6.8 2.5 3.0 8.6 9.7 4.3 10.9 10.0 5.2 105.2 92.0 86.9 
UC 3.7 4.4 4.6 9.3 2.8 2.0 10.0 5.2 5.0 97.8 93.0 91.6 
Cotinine 
PL 5.3 3.9 3.2 2.5 3.4 4.3 5.9 5.2 5.4 102.6 104.2 93.1 
UC 4.1 3.2 4.2 6.1 4.7 7.2 7.4 5.7 8.3 105.0 94.0 96.3 
OH-
Cotinine 
PL 5.9 4.0 5.5 10.3 7.5 7.5 11.8 8.5 9.3 93.5 89.1 90.2 
UC 7.6 4.0 2.2 9.6 4.4 9.2 12.2 6.0 9.4 98.5 89.1 91.3 
OH-Cotinine: hydroxycotinine; PL: placenta; UC: umbilical cord 
Table 4. Matrix effect, extraction efficiency and process efficiency results in placenta 673 





Matrix effect (%) 
(%CV) (n=10) 
Extraction efficiency 
(%) (%CV) (n=6) 
Process efficiency (%) 
(n=6) 














































































































Table 5. Average analyte concentrations (ng/g) and %CV found in 4 different placenta 684 
locations and 2 different umbilical cord locations from participants A to I. Analyte 685 
concentrations (ng/g) in placenta and umbilical cord specimens from participants J to N. 686 
Paired hair concentrations found for nicotine and cotinine in the third trimester are 687 
expressed in ng/g.   688 
Case 
Placenta Umbilical cord Hair 
Nicotine  Cotinine  OH-Cotinine  Nicotine  Cotinine  
OH-
Cotinine  Nicotine  Cotinine  






(3.6%) <LOD 72.7 










(4.5%) *10297.7  *323.2 










(2%) 1447.8  433.8 










(10.9%) 265.9 <LOD 






(1.2%) 541.5 109.4 










(0.2%) 3403.3 339.4 








(8.2%) 1167.2 416.3 
H <LOD <LOQ <LOQ <LOD 6.7 (14.7%) <LOQ <LOD <LOD 






(0.0%) 15428.3 668.5 
J 6.7 23.1 19.3 8.8 18.5 17.5 2705.4 168.4 
K 8.5 39.7 18.8 12.8 50.2 38.6  10313.1 <LOD 
L 7.6 17.6 16.6 9.6 20.6 28.8 *1733.5 *<LOD 
M 5.7 7.1 8.3 6.4 10.6 12.9  *1770.5 *<LOD 
N <LOD 6.8 <LOD 7.8 9.7 6.7 *1845.1 *112.7 













Figure captions 701 
Figure 1. Chromatograms of the MRM transitions for nicotine, cotinine and 702 
hydroxycotinine (OH-cotinine) in a blank placenta sample (1a), and in placenta fortified 703 
at the LOQ (5 ng/g) (1b).  704 
Figure 2. Chromatograms of the MRM transitions for nicotine, cotinine and 705 
hydroxycotinine (OH-cotinine) in a blank umbilical cord sample (2a), and in umbilical 706 
cord fortified at the LOQ (5 ng/g) (2b).  707 
Figure 3. Chromatograms of the MRM transitions for nicotine, cotinine and 708 
hydroxycotinine (OH-cotinine) in the placenta (3a) and umbilical cord (3b) from a 709 
positive real specimen (Case L). Nicotine, cotinine and OH-cotinine concentrations 710 
were 7.6, 17.6 and 16.6 ng/g, respectively, in placenta; and 9.6, 20.6 and 28.8 ng/g in 711 
umbilical cord. 712 
 713 
